Lovisa Afzelius MBA, PhD

Personal: Founding CEO and Board Chair at Apriori. General partner at Flagship Pioneering and serial entrepreneur; Founding CEO of Alltrna, Metaphore Biotechnologies, and Prologue Medicines. Prior to joining Flagship in 2020, she built and led Pfizer’s systems immunology function and served as Executive Director of Clinical Programs.
Lovisa began her career at AstraZeneca in 1999 and has received numerous accolades for her work, including being named one of the 100 “most influential persons under 40 in Sweden” by the business magazine, Affärsvärlden. In 2022, Lovisa Afzelius, was named one of the 20 women blazing trails in biopharma Endpoints (https://endpts.com/special-report-2022-meet-20-women-blazing-trails-in-biopharma-rd/) for her work with companies using AI and machine learning to advance drug development. In 2023, Apriori Bio was named a Technology Pioneer by the World Economic Forum and received an honorable mention for Fast Company’s World Changing Ideas list in the Rapid Response category.
She holds a Ph.D. in computational chemistry from Uppsala University, a Master of Science in integrative pharmacology from Gothenburg University as well as an M.B.A. from MIT.